VectivBio

Transforming Lives

Investors & Media

VectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies that have the potential to meaningfully transform and improve the lives of patients.

Latest Presentation

Recent News and Upcoming Events

PRESS RELEASES

Apr 13, 2021

VectivBio Announces Closing of $146.6 Million Initial Public Offering

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a

Read More View All

EVENTS & PRESENTATIONS

More events are coming soon.

Stock Performance Summary

Change
Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.